What is Humatrope HGH

What is Humatrope?

Humatrope® (somatropin [rDNA origin] for injection) is a treatment made by Eli Lilly and Company. Humatrope is a bio-identical form of human growth hormone, produced using recombinant DNA technology. Bio-identical means that Humatrope is molecularly identical to that which is produced by the human body, it just comes from a lab rather than from the pituitary gland.

What is Humatrope used for?

Humatrope Therapy for Children and Adolescents
Humatrope is used for the treatment of conditions that are associated with pediatric and adult human growth hormone deficiency. For pediatric Patients, Humatrope is indicated for the long-term treatment of patients who have growth failure due to an inadequate secretion of normal endogenous growth hormone. Humatrope is indicated for the treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed. Humatrope helps children that have trouble growing because of human growth hormone deficiency reach their normal final adult height. Humatrope can only be used for this purpose until the epiphyseal plates have closed, because, after these structures have closed, height is essentially “locked in,” and the patient can no longer grow taller.

Humatrope

Beyond this point, providing HGH levels associated with childhood will lead to symptoms of acromegaly, in which the bones become thicker and wider without becoming longer. Humatrope is used for the extended treatment of idiopathic short stature, defined by height SDS ≤-2.25, and used with growth rates unlikely to achieve a normal range of adult heights, in patients whose epiphyses are not closed and for whom evaluation excludes other possible causes associated with short height stature that should be treated by other means.

Humatrope Therapy for Adults
For adult patients, Humatrope is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency. Adult Human Growth Hormone Deficiency comes in two forms: 1. Adult Onset: Patients who have growth hormone deficiency as a result of pituitary disease, radiation therapy, hypothalamic disease, surgery, or trauma. Adult onset HGH deficiency can also be the result of age related natural HGH decline, in which the body slowly loses its ability to produce sufficient HGH to meet the needs of the body after the age of thirty. 2. Childhood Onset: Patients who were HGH deficient during childhood who have growth hormone deficiency confirmed as an adult before replacement therapy with Humatrope is started. Although Humatrope only encourages growth until the end of puberty, the patient still needs human growth hormone to sustain normal cellular metabolism and can benefit from a reduced dosage of Humatrope.

Humatrope Dosages

Pediatric Patients

The Humatrope dosage and administration schedule should be individualized for each patient. Therapy should not be continued if epiphyseal fusion has occurred. Response to growth hormone therapy tends to decrease with time. However, failure to increase growth rate, particularly during the first year of therapy, should prompt close assessment of compliance and evaluation of other causes of growth failure such as hypothyroidism, under-nutrition and advanced bone age. Growth hormone-deficient pediatric patients – The recommended weekly dosage is 0.18 mg/kg (0.54 IU/kg) of body weight. The maximal replacement weekly dosage is 0.3 mg/kg (0.90 IU/kg) of body weight. It should be divided into equal doses given either on three alternate days, six times per week or daily. The intravenous route of administration is the preferred method. The dosage and administration schedule for Humatrope should be individualized for each patient. Turner Syndrome – A weekly dosage of up to 0.375 mg/kg (1.125 IU/kg) of body weight administered by subcutaneous injection is recommended. It should be divided into equal doses given either daily or on 3 alternate days. Patients with idiopathic short stature – A weekly dosage of up to 0.37 mg/kg of body weight administered by subcutaneous injection is recommended. It should be divided into equal doses given 6 to 7 times per week.

Adult Patients

Growth hormone-deficient adult patients – The recommended dosage at the start of therapy is not more than 0.006 mg/kg/day (0.018 IU/kg/day) given as a daily subcutaneous injection. The dose may be increased according to individual patient requirements to a maximum of 0.0125 mg/kg/day (0.0375 IU/kg/day).

About Eli Lily

Founded in 1876 by Colonel Eli Lily is a globe spanning research and pharmaceutical firm with it’s headquarters in Indianapolis, Indiana. The firm did North of $24 billion in revenue in 2011 and spends $5 billion dollars a year in research alone. The company has 38,000 employees and manufacturing plants in 13 countries.